By Giulia Petroni

Roche said that its Elecsys IL-6 test was approved in countries carrying the "CE" safety mark to help diagnose neonatal sepsis, one of the leading causes of death in newborns.

Neonatal sepsis is an infection involving the bloodstream within the first four weeks of life, and can rapidly progress to multisystem organ failure. An early diagnosis can potentially decrease mortality rates and mitigate long-term consequences, the Swiss pharmaceutical giant said Wednesday.

Elecsys IL-6, which is used to identify severe inflammatory responses in patients, takes 18 minutes to run and only a small amount of blood, Roche said.

Write to Giulia Petroni at giulia.petroni@wsj.com

(END) Dow Jones Newswires

October 18, 2023 01:39 ET (05:39 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Roche (QX) (USOTC:RHHBY)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Roche (QX)
Grafico Azioni Roche (QX) (USOTC:RHHBY)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Roche (QX)